Capital International Investors Buys 243,487 Shares of CRISPR Therapeutics AG $CRSP

by · The Markets Daily

Capital International Investors boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,892,745 shares of the company’s stock after acquiring an additional 243,487 shares during the period. Capital International Investors owned 0.06% of CRISPR Therapeutics worth $309,016,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in CRSP. Ramirez Asset Management Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $26,000. Rothschild Investment LLC boosted its holdings in CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares in the last quarter. Optiver Holding B.V. boosted its holdings in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after acquiring an additional 210 shares in the last quarter. Finally, Strategic Advocates LLC bought a new stake in CRISPR Therapeutics in the third quarter valued at $34,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $51.84 on Monday. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $5.00 billion, a P/E ratio of -8.33 and a beta of 1.74. The business has a fifty day simple moving average of $52.03 and a two-hundred day simple moving average of $53.12. CRISPR Therapeutics AG has a 12 month low of $39.58 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. On average, equities analysts forecast that CRISPR Therapeutics AG will post -4.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRSP has been the topic of several recent analyst reports. Needham & Company LLC lifted their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 13th. Chardan Capital lifted their price target on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th. Truist Financial upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Evercore reiterated an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.47.

Check Out Our Latest Report on CRISPR Therapeutics

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 3,450 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $166,497.00. Following the transaction, the general counsel directly owned 91,240 shares of the company’s stock, valued at $4,403,242.40. This represents a 3.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 46,535 shares of company stock valued at $2,311,300. 4.30% of the stock is currently owned by company insiders.

CRISPR Therapeutics Profile

(Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

See Also

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).